Bioactive Products
| A unique collection of 674 anticancer natural compounds for high throughput screening (HTS) and New anticancer drug research | ||
| Catalog No: | B91 | Anticancer Compound Library Screening Details |
| Size: | 1mg/well * 674 Compounds 2mg/well * 674 Compounds | |
| Cat. No. | Information |
| CFN99689 | Yunnancoronarin A Yunnancoronarin A shows cytotoxicity against the lung adenocarcinoma cells A549 and leukemia cells K562, with the IC(50) value of 2.20 microM. |
| CFN99806 | Epifriedelanol Epifriedelanol has antitumor activity, it can reduce cellular senescence in human primary cells and may be used to develop dietary supplements or cosmetics that modulate tissue aging or aging-associated diseases. Epifriedelanol exhibits significant inhibition of NF-kappa B, it may be used to treat asthma. |
| CFN99810 | 2-Hydroxy-3-methylanthraquinone 2-Hydroxy-3-methylanthraquinone enhances apoptosis of U937 cells,in part,through activation of p-p38MAPK and downregulation of p-ERK1/2; triggers caspase-3 activation mediated apoptotic induction. |
| CFN99814 | Rhoifolin Rhoifolin possesses a variety of significant biological activities including antioxidant, anti-inflammatory, antimicrobial, hepatoprotective and anticancer effects, it may be beneficial for diabetic complications through its enhanced adiponectin secretion, tyrosine phosphorylation of insulin receptor-β and GLUT4 translocation. Rhoifolin has a radioprotective effect against radiation-induced decrease of blood platelets and cardiac biochemical lesions in whole body irradiated mice. |
| CFN99815 | Ganoderic acid DM Ganoderic acid DM is an antiandrogenic osteoclastogenesis inhibitor, it especially suppresses the expression of c-Fos and nuclear factor of activated T cells c1 (NFATc1), this suppression leads to the inhibition of dendritic cell-specific transmembrane protein (DC-STAMP) expression and reduces osteoclast fusion. Ganoderic acid DM has shown toxicity to both androgen-dependent and independent prostate cancer cells with reduced osteoclastogenesis in late stage metastatic disease, it may an alternative agent for the treatment of advanced prostate cancer. |
